| ID | 1117 |
| Name of the vaccine | Typherix |
| Microbe | Bacteria |
| Disease name | Typhoid |
| Name of bacteria | Salmonella typhi |
| Type of vaccine | Inactivated |
| Nucleic acid content | DNA |
| Age | Over 2 years |
| Description of the vaccine | Vi polysaccharide typhoid vaccine. |
| Name of the manufacturer | GlaxoSmithKline Biologicals |
| Name of the manufacturing country | Belgium |
| Year of manufacture | 2001 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram negative bacteria. |
| Efficacy | NA |
| Vaccine formulation | Solution for injection |
| Dosage | Single dose of 0.5 mL.
Subjects who remain at risk should be revaccinated using a single dose every 3 years. |
| Mechanism of action | Production of IgG antibodies and is T cell independent. |
| Route of administration | Intramuscular |
| Indications | Against typhoid fever for adults and children. |
| Export | Marketing Authorisation Holder - GlaxoSmithKline (Thailand) Ltd. |
| Approval | WHO and European Pharmacopoeia |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Redness, pain, swelling, fever, headache, general aches, malaise, nausea and itching. |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | 24599532 |
| Clinical trial number | NA |
| Reference | https://www.fda.moph.go.th/sites/drug/Summary/1C_1_44_NG_Typherix.pdf |
| Other name | NA |
| Additional Links | NA
|